About geographic atrophy geographic atrophy is the advanced form of atrophic AMD. According to data published in Archives of Ophthalmology approximately 973,000 people in the U.S. Had GA in at least one eye on 2004. This figure is more than 50 more than 50 percent by 2020. Currently, there are no therapeutic treatment for GA.

Sirion Therapeutics Initiates Enrollment Of Phase II clinical trial for the treatment of geographic atrophySirion Therapeutics, an ophthalmic-focused biopharmaceutical company, announced today that it commenced enrollment of a Phase II clinical study evaluating fenretinide in the treatment of geographic atrophy in patients with age-related macular degeneration.Study compared use of an OC solely to the same OC with the addition of of an oral androgen . The study was conducted by Dr. Rik van Lunsen and Dr. Ellen Laan of of the Department for sexual Research of the the Academic Medical Center in Amsterdam, The Netherlands carried out in close collaboration with a professor Herjan Coelingh Bennink and Dr. Yvette Zimmermann from Pantarhei Biosciences in the Netherlands. Initial findings were 20 May 2010 at the 11th Conference of the European Society on Contraception at The Hague, in women who as Additional data will are reported according to of full release which results of the survey.